China Jo-Jo Drugstores, Inc. (CJJD)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
China Jo-Jo Drugstores, Inc. (CJJD) trades at $1.52 with AI Score 42/100 (Grade C). China Jo-Jo Drugstores, Inc. operates as a retailer and distributor of pharmaceutical and healthcare products in China. Market cap: $9.95M, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for CJJD: CJJD does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CJJD against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CJJD: the 1 perspectives are evenly split.
How is this calculated? →China Jo-Jo Drugstores, Inc. (CJJD) Healthcare & Pipeline Overview
China Jo-Jo Drugstores, Inc. retails and distributes pharmaceutical and healthcare products in China, operating through retail drugstores, online platforms, wholesale, and herb farming. With a focus on traditional Chinese medicine (TCM) and Western medicine, the company operates retail pharmacies and online stores, facing competition in China's evolving healthcare market.
What Is the Investment Thesis for CJJD?
China Jo-Jo Drugstores, Inc. presents a unique investment proposition within the Chinese healthcare market, characterized by its integrated approach to retail pharmacy, online sales, wholesale distribution, and herb farming. With a market capitalization of $9.95M and a P/E ratio of 0.0, the company's valuation metrics suggest potential undervaluation relative to its earnings. The company's profit margin of 8.5% and gross margin of 3.2% indicate areas for improvement in operational efficiency and cost management. Key growth catalysts include expanding its online pharmacy presence to capitalize on the growing e-commerce trend in China, and leveraging its TCM herb farming operations to meet increasing demand for traditional medicine. However, investors may want to evaluate the potential risks associated with operating in a highly regulated market, including evolving healthcare policies and pricing pressures. The company's beta of -0.15 suggests a low correlation with the broader market, potentially offering downside protection during market downturns.
Based on FMP financials and quantitative analysis
CJJD Key Highlights
- Market capitalization of $9.95M, indicating a small-cap company with potential for growth.
- P/E ratio of 0.0, suggesting the company may be undervalued compared to its earnings.
- Profit margin of 8.5%, reflecting the company's profitability in the pharmaceutical retail sector.
- Gross margin of 3.2%, indicating the percentage of total sales revenue that the company retains after incurring the direct costs associated with producing the goods and services it sells.
- Operated 109 retail pharmacies under the Jiuzhou Grand Pharmacy name, as well as 4 drugstores as of March 31, 2021, demonstrating a significant retail presence.
Who Are CJJD's Competitors?
CJJD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AGRX Agile Therapeutics, Inc. | $1.51 | +3.42% | $10.43M | 59 |
| APGN Apexigen, Inc. | $0.39 | +8.48% | $9.57M | 44 |
| CNTG Centogene N.V. | $0.33 | +100.00% | $9.42M | 50 |
| ETAO ETAO International Co., Ltd. | $1.91 | -31.79% | $9.78M | 42 |
| FTRP Field Trip Health Ltd. | $0.84 | +1.07% | $9.81M | 62 |
| ATAI Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company | $5.19 | +6.35% | $1.91B | 68 |
| MEDS TRxADE HEALTH, Inc. | $7.59 | +4.55% | $13.28M | 63 |
| ONC BeOne Medicines Ltd. | $297.65 | +2.38% | $31.81B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CJJD's Key Strengths?
- Established retail pharmacy network in China.
- Integration of traditional Chinese medicine (TCM) with Western medicine.
- Online pharmacy platform providing convenient access to healthcare products.
- Herb farming operations ensuring a stable supply of TCM ingredients.
What Are CJJD's Weaknesses?
- Relatively small market capitalization compared to larger competitors.
- Gross margin of 3.2% indicates potential inefficiencies.
- Limited geographic diversification outside of China.
- Dependence on regulatory approvals for pharmaceutical products.
What Could Drive CJJD Stock Higher?
- Expansion of online pharmacy platform to increase market reach and sales.
- Leveraging TCM expertise to develop new products and services for domestic and international markets.
- Strategic partnerships with other healthcare providers or technology companies to enhance capabilities.
- Efforts to improve operational efficiency and increase profit margins.
What Are the Key Risks for CJJD?
- Financial-distress signal — its Altman Z-Score of 1.39 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Intense competition from other pharmaceutical retailers and online pharmacies.
- Evolving healthcare regulations and pricing pressures in China.
- Product recalls or safety concerns related to pharmaceutical products.
- Fluctuations in the cost of raw materials for TCM herbs.
- Dependence on regulatory approvals for pharmaceutical products.
What Are the Growth Opportunities for CJJD?
- Expansion of Online Pharmacy Platform: China Jo-Jo Drugstores can capitalize on the increasing e-commerce penetration in China by expanding its online pharmacy platform. The Chinese online pharmacy market is projected to reach $49.7 billion in 2026, presenting a significant growth opportunity. By enhancing its online platform with a wider range of products, improved user experience, and strategic partnerships with e-commerce giants, the company can attract a larger customer base and drive online sales growth. Timeline: Ongoing.
- Leveraging Traditional Chinese Medicine (TCM): With the growing popularity of TCM in China and globally, China Jo-Jo Drugstores can leverage its herb farming operations to meet the increasing demand for TCM products. The global TCM market is expected to reach $200 billion by 2025. By expanding its herb cultivation and processing capabilities, the company can ensure a stable supply of high-quality TCM ingredients and develop new TCM-based products for both domestic and international markets. Timeline: Ongoing.
- Strategic Partnerships and Acquisitions: China Jo-Jo Drugstores can pursue strategic partnerships and acquisitions to expand its market reach and product offerings. Collaborating with other healthcare providers, pharmaceutical manufacturers, or technology companies can create synergies and enhance the company's competitive position. Acquiring smaller pharmacy chains or healthcare-related businesses can accelerate its expansion into new geographic areas or product categories. Timeline: Upcoming.
- Enhancing Retail Pharmacy Network: While already having a retail presence, China Jo-Jo Drugstores can optimize its existing network of retail pharmacies by improving store layouts, product assortment, and customer service. Implementing data analytics to understand customer preferences and optimize inventory management can enhance sales and profitability. Expanding the range of healthcare services offered at its pharmacies, such as health screenings and consultations, can also attract more customers. Timeline: Ongoing.
- Expanding Drug Wholesale Business: China Jo-Jo Drugstores can increase its revenue by expanding its drug wholesale business. By establishing partnerships with more pharmaceutical manufacturers and distributors, the company can increase the volume of products it distributes. Focusing on niche or specialized pharmaceutical products can also provide a competitive advantage. Timeline: Ongoing.
What Opportunities Does CJJD Have?
- Expansion of online pharmacy platform to reach more customers.
- Leveraging TCM expertise to develop new products and services.
- Strategic partnerships and acquisitions to expand market reach.
- Increasing demand for healthcare products and services in China.
What Threats Does CJJD Face?
- Intense competition from other pharmaceutical retailers and online pharmacies.
- Evolving healthcare regulations and pricing pressures in China.
- Potential for product recalls or safety concerns.
- Fluctuations in the cost of raw materials for TCM herbs.
What Are CJJD's Competitive Advantages?
- Established retail pharmacy network in China.
- Integration of traditional Chinese medicine (TCM) with Western medicine.
- Online pharmacy platform providing convenient access to healthcare products.
- Herb farming operations ensuring a stable supply of TCM ingredients.
What Does CJJD Do?
Founded in 2003 and headquartered in Hangzhou, China, China Jo-Jo Drugstores, Inc. has evolved into a multifaceted healthcare company operating across various segments of the pharmaceutical industry. The company's primary business involves retailing and distributing pharmaceutical products, including prescription and over-the-counter drugs, nutritional supplements, traditional Chinese medicines (TCM), personal and family care products, and medical devices. These products are offered through its network of retail drugstores, operating under the Jiuzhou Grand Pharmacy name, and its online pharmacy platforms. The company also provides convenience products, such as consumable, seasonal, and promotional items. China Jo-Jo Drugstores distinguishes itself by integrating traditional and Western medical practices, offering on-site consultations with licensed doctors of Western medicine and TCM. This approach caters to a broad customer base seeking both conventional and alternative healthcare solutions. In addition to its retail operations, the company engages in drug wholesale, distributing third-party pharmaceutical products to trading companies. It also cultivates and wholesales herbs used for TCM, further diversifying its revenue streams. As of March 31, 2021, China Jo-Jo Drugstores operated 109 retail pharmacies under the Jiuzhou Grand Pharmacy name, along with 4 additional drugstores, demonstrating its established presence in the Chinese pharmaceutical retail market.
What Products and Services Does CJJD Offer?
- Operates retail drugstores under the Jiuzhou Grand Pharmacy name.
- Sells prescription and over-the-counter drugs.
- Offers nutritional supplements and traditional Chinese medicines (TCM).
- Provides personal and family care products and medical devices.
- Operates an online drugstore retailing OTC drugs and nutritional supplements.
- Sells products through third-party online platforms.
- Distributes third-party pharmaceutical products to trading companies.
- Cultivates and wholesales herbs used for TCM.
How Does CJJD Make Money?
- Retail sales of pharmaceutical products through physical stores.
- Online sales of pharmaceutical products through its online pharmacy.
- Wholesale distribution of pharmaceutical products to other companies.
- Cultivation and sale of herbs used in traditional Chinese medicine.
What Industry Does CJJD Operate In?
China Jo-Jo Drugstores operates within the rapidly evolving Chinese healthcare market, which is characterized by increasing demand for pharmaceutical products and healthcare services. The market is driven by factors such as an aging population, rising disposable incomes, and growing awareness of health and wellness. The competitive landscape includes both domestic and international players, ranging from large pharmaceutical manufacturers to retail pharmacy chains. China Jo-Jo Drugstores differentiates itself through its integrated business model, combining retail pharmacy, online sales, wholesale distribution, and herb farming. The company's focus on traditional Chinese medicine (TCM) also provides a unique selling proposition in a market where TCM remains highly valued.
Who Are CJJD's Key Customers?
- Individual consumers seeking prescription and over-the-counter medications.
- Customers interested in nutritional supplements and personal care products.
- Patients seeking traditional Chinese medicine (TCM) remedies.
- Trading companies purchasing pharmaceutical products for distribution.
ROE 42%Key Financial Metrics
Return on equity for China Jo-Jo Drugstores, Inc. stands at 41.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 20.2%, showing how much profit it generates from its asset base. CJJD trades at a trailing price-to-earnings ratio of 0.00, below the Healthcare sector average of ~23x. A current ratio of 1.82 indicates the company holds enough short-term assets to cover its near-term obligations.
China Jo-Jo Drugstores, Inc. (CJJD) Valuation Context
Valued at $9.95M, CJJD is classified as a micro-cap stock. Relative to its peer group, CJJD's quantitative score of 42/100 is roughly in line with the peer average of 51/100.
Company Profile
China Jo-Jo Drugstores, Inc. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Hangzhou, CN. The company is led by CEO Lei Liu. CJJD has traded publicly since 2009.
F-Score 3/9Financial Health
China Jo-Jo Drugstores, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 1.39 places it in the distress zone, a signal of elevated financial risk.
CJJD Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- CJJD's recent insider buying suggests those in the know see value, signaling potential upside.
- The community buzz around CJJD lately is surprisingly positive, indicating growing investor interest.
- There's a perception that CJJD is undervalued, with many believing it's poised for a rebound.
- Recent market developments favor companies with CJJD's profile, potentially boosting its performance.
Bear Case
- Insider activity could be strategic, not necessarily reflecting genuine confidence in CJJD's long-term prospects.
- Community sentiment can be fickle; positive buzz might be short-lived and based on speculation.
- The 'undervalued' perception might stem from overlooking fundamental weaknesses in CJJD's business model.
- Market conditions are volatile; factors favoring CJJD now could easily reverse, creating headwinds.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
CJJD Latest News
No recent news available for CJJD.
CJJD Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CJJD.
Price Targets
Wall Street price target analysis for CJJD.
CJJD MoonshotScore
What does this score mean?
The MoonshotScore rates CJJD's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Lei Liu
CEO
Lei Liu is the Chief Executive Officer of China Jo-Jo Drugstores, Inc. His background encompasses extensive experience in the pharmaceutical retail sector in China. Details regarding his specific educational background and prior roles are not available. As CEO, he is responsible for overseeing the company's strategic direction, operational performance, and financial results. He manages a workforce of 939 employees.
Track Record: Since becoming CEO, Lei Liu has focused on expanding the company's online presence and leveraging its traditional Chinese medicine (TCM) capabilities. Specific milestones and achievements under his leadership are not available, but the company continues to operate in a competitive market. He is responsible for navigating the evolving regulatory landscape and driving growth in the Chinese healthcare market.
What Investors Ask About China Jo-Jo Drugstores, Inc. (CJJD) — Healthcare
What does China Jo-Jo Drugstores, Inc. do?
China Jo-Jo Drugstores, Inc. operates as a retailer and distributor of pharmaceutical and healthcare products in the People's Republic of China. The company operates through four segments: Retail Drugstores, Online Pharmacy, Drug Wholesale, and Herb Farming. Its stores provide various pharmaceutical products, including prescription and over-the-counter drugs, nutritional supplements, traditional Chinese medicines (TCM), personal and family care products, and medical devices, as well as convenience products. The company also operates licensed doctors of Western medicine and TCM on site for consultation, examination, and treatment of common ailments at scheduled hours.
What are the main risks for CJJD?
China Jo-Jo Drugstores faces several risks inherent to the pharmaceutical retail and distribution industry in China. These include intense competition from both domestic and international players, evolving healthcare regulations and pricing pressures, potential for product recalls or safety concerns, and fluctuations in the cost of raw materials for TCM herbs. The company's dependence on regulatory approvals for pharmaceutical products also poses a risk to its operations and growth prospects. Investors should carefully consider these risks before investing in CJJD.
How does China Jo-Jo Drugstores, Inc. ensure the quality and safety of its pharmaceutical products?
China Jo-Jo Drugstores, Inc. operates in a highly regulated industry and is subject to stringent quality control standards and regulations. While specific details on the company's quality assurance processes are not available, it is expected that the company adheres to all applicable regulations and implements measures to ensure the safety and efficacy of its pharmaceutical products. This includes sourcing products from reputable suppliers, conducting quality testing, and maintaining proper storage and handling procedures. Compliance with these standards is essential for maintaining the company's reputation and avoiding potential liabilities.
What revenue streams does China Jo-Jo Drugstores, Inc. have in healthcare?
China Jo-Jo Drugstores, Inc. generates revenue from multiple streams within the healthcare sector. The primary revenue stream is the retail sale of pharmaceutical products, including prescription and over-the-counter drugs, nutritional supplements, and medical devices, through its network of retail drugstores. The company also generates revenue from its online pharmacy platform, selling OTC drugs and nutritional supplements. Additional revenue streams include the wholesale distribution of pharmaceutical products to trading companies and the cultivation and sale of herbs used in traditional Chinese medicine (TCM).
What are the key factors to evaluate for CJJD?
China Jo-Jo Drugstores, Inc. (CJJD) holds an AI score of 42/100 (low). P/E: 0.0x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does CJJD data refresh on this page?
CJJD prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CJJD's recent stock price performance?
China Jo-Jo Drugstores, Inc. (CJJD) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established retail pharmacy network in China. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CJJD overvalued or undervalued right now?
China Jo-Jo Drugstores, Inc. (CJJD) trades at 0.0x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis is pending for CJJD, which may provide further insights.
- The Chinese healthcare market is subject to regulatory and economic uncertainties.